Navigation Links
Northwest Bio Announces Interview of CEO Linda Powers in Today's CEO/CFO Publication
Date:11/1/2011

BETHESDA, Md., Nov. 1, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (Northwest Bio) today announced, as part of its program of public outreach and education, the availability online of an interview of Northwest Bio Chairman and CEO Linda Powers by CEO/CFO Publication.

(Logo:  http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The interview describes in layman's terms both the encouraging science behind DCVax® and the progress now being made in both the US and Europe towards being able to make this promising technology available to cancer patients.

By way of historical background, Ms. Powers observes that, "What attracted me to Northwest Biotherapeutics was that they have a platform technology that should be applicable to pretty much all cancers, and which is offering really a major improvement in survival times for patients, with no toxicity. The drugs that are out there today typically only add ten weeks of survival and they have a heck of a toxicity profile. Therefore, the combination of the effectiveness, the lack of toxicity, and the fact that it may be applicable to any cancer really was very exciting."

In describing the technology, Ms. Powers noted, "The key to the Northwest technology was figuring out, number one, which type of immune cell is the master immune cell. In other words, who the General of the Army is, because if you are going to give the key signals, the marching orders, you have to give them to the right party who can implement them. Therefore, one key thing was figuring out that the dendritic cells are the master cells of the immune system. The immune system has so many players."

The full interview is available on the Company's website, www.nwbio.com as well as on http://ceocfointerviews.com, CEO/CFO Publication's website.


'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NORTHWEST BIO Announces Positive Third Quarter Progress
2. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
3. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
4. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
5. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
6. Northwest Biotherapeutics Announces Change and Expansion of Management Team
7. Northwest Biotherapeutics Announces Series of Financing Arrangements
8. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
9. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
10. Northwest Biotherapeutics Addresses Recent Market Activity
11. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... (PRWEB) March 01, 2015 Market ... agreement for quality market research promotion on Internet. ... research reports worked out by DataGroup Booksellers. , ... Market Publishers Ltd, commented on the recent partnership ... DataGroup Booksellers in our team of publishers. Since ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 Immunovaccine ... made aware of a fraudulent press release disseminated this ... to be from Immunovaccine. This press release states that ... Science, Inc. The press release did not originate ... information contained within the press release. Please note ...
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... for its newly developed Bruton,s tyrosine kinase (BTK) ... completed. The results of these preclinical evaluations have ... Administration. The feedback received from the Agency is ... study. Additional preclinical work is required to begin ...
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
Breaking Biology Technology:Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2
... COATED PLATE ASSAYS , ... the counting of radioimmunoassays based on coated microtitration plates. The following method ... compare the standard immunoassay microtitration plates with those manufactured by PerkinElmer Life ... procedure is straightforward: , (1) Coat ...
... , ... Dpartement dImmunologie, Laboratoires Fournier S.A., France ... TGF- type I and type II receptors ... type II (TRII) tends to act as the primary receptor. In the ...
... L. Smith1, M.J. Price-Jones 1 , K.T. ... plc., Forest Farm, Whitchurch, Cardiff, CF4 7YT, Wales, UK, 2 PerkinElmer ... , INTRODUCTION ... a multi-detector instrument designed for liquid scintillation (LS) or luminescence detection of samples ...
Cached Biology Technology:Coated Plate Immunoassay on the MicroBeta - eg. TSH - IRMA 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 2Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 3Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 4Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 5Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 6Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor 7Counting Cytostar-T scintillating microplates on the MicroBeta JET 2Counting Cytostar-T scintillating microplates on the MicroBeta JET 3Counting Cytostar-T scintillating microplates on the MicroBeta JET 4Counting Cytostar-T scintillating microplates on the MicroBeta JET 5
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... upcoming RedChip Global Online CEO Conference on January 29 ... Gino Pereira , CEO of NXT-ID will present ... product, the Wocket smart wallet and its full suite ...
(Date:2/5/2015)... VIEW, Calif. , Feb. 3, 2015 /PRNewswire/ ... printer technology, demand from industries such as consumer ... global market for surface mount technology (SMT) screen ... equipment to automatic control will push the adoption ... dispensers will remain steady as glue dispensers are ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... Philadelphia, PA, May 2, 2012 Although the ... associated. Individuals with epilepsy are more likely to have ... risk factor for psychosis. It is not known whether ... of psychosis is a risk factor for epilepsy. ...
... Infants born to women who used the anti-HIV drug tenofovir ... not weigh less at birth and are not of shorter ... regimens that do not include tenofovir during pregnancy, according to ... However, at 1 year of age, children born to ...
... to sneak up on a huge dinosaur while it sleeps, crawl ... have felt like a needle going in but giant "flea-like" ... just that. And a few actually lived through the experience, ... these creatures, just announced in Current Biology, a professional ...
Cached Biology News:Evidence of familial vulnerability for epilepsy and psychosis 2Anti-HIV drug use during pregnancy does not affect infant size, birth weight 2Anti-HIV drug use during pregnancy does not affect infant size, birth weight 3Jurassic pain: Giant 'flea-like' insects plagued dinosaurs 165 million years ago 2
... Immulon 2HB ELISA ... provide increased binding affinity for hydrophilic ... bottom works well for reagent injection ... Each strip accomodates ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... positively and negatively supercoiled DNA in presence of ... the effects of supercoiling on transcription in vitro ... , Determining the degree of supercoiling of naturally ... differ in length by only one base-pair ...
... Kit for Kilo-Sequencing is designed to aid ... into the multiple cloning sites (MCS) of ... or phagemid vectors (pUC18/19). The kit is ... the target DNA, thereby progressively moving the ...
Biology Products: